XC3-28174-89123
3 vaccinations
1 coded response
13 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 606 / IL
- Registered
- 2021-12-09
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-04-21
Dose 1 — Pfizer-BioNTech
-
2021-05-12
Dose 2 — Pfizer-BioNTech
-
2021-12-09
Registered in v-safe
-
2021-12-09
Dose 3 — Pfizer-BioNTechCo-administered: Flu
- 2021-12-09
- 2021-12-10
- 2021-12-11
- 2021-12-12
- 2021-12-13
- 2021-12-14
- 2021-12-15
- 2021-12-16
- 2022-01-06
- 2022-01-13
-
2022-03-10
Survey response — 3 months, dose 3MedDRA: Influenza, Nasopharyngitis — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Cold / Flu symptoms (24 hours)MedDRA releases: 2024-11 · check-in free text available
- 2022-06-09
- 2022-12-12
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-04-21 | Pfizer-BioNTech | No |
| 2 | 2021-05-12 | Pfizer-BioNTech | No |
| 3 | 2021-12-09 | Pfizer-BioNTech | Flu |
Free text
Release 11 — 3 months, dose 3
Symptoms: Cold / Flu symptoms (24 hours)
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Influenza | · | · | ✓ |
| SD | Nasopharyngitis | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release